Evidence map›Paper›PMID 39996090›Full record

ArticleJTO clinical and research reports2025

Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC.

Helena Bote-de Cabo, Marco Siringo, Esther Conde, Susana Hernández, Fernando López-Ríos, Alicia Castelo-Loureiro, Esther García-Lorenzo, Javier Baena, Mercedes Herrera, Ana Belén Enguita and 3 more

Abstract read
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Identification ofOncology research · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Clinical Utility of ctDNA Analysis in Lung Cancer-A Review.Advances in respiratory medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Helena Bote-de CaboDepartment of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.
Marco SiringoDepartment of Medical Oncology, Sapienza University of Rome, Italy.
Esther CondeComplutense University, Madrid, Spain.
Susana HernándezDepartment of Pathology, 12 de Octubre University Hospital, Madrid, Spain.
Fernando López-RíosComplutense University, Madrid, Spain.
Alicia Castelo-LoureiroDepartment of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Esther García-LorenzoSTART Madrid-FJD, Early Phase Clinical Trials Unit, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Javier BaenaDepartment of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.
Mercedes HerreraDepartment of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.
Ana Belén EnguitaDepartment of Pathology, 12 de Octubre University Hospital, Madrid, Spain.
Yolanda RuanoDepartment of Pathology, 12 de Octubre University Hospital, Madrid, Spain.
Jon ZugazagoitiaDepartment of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.
Luis Paz-AresDepartment of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.

Funding

NIMHD NIH HHS L60 MD007437
6 · The paper itself

Abstract

Introduction: Tissue and plasma-based next-generation sequencing (NGS) have complementary roles in patients with advanced NSCLC. Nevertheless, whether there is any added clinical value in combining both methods in the treatment of naïve patients remains unclear. Methods: We retrospectively collected clinical and genomic data from 275 patients with treatment-naïve advanced NSCLC who had undergone plasma-based NGS at diagnosis in our institution. We analyzed patient data in two separate cohorts, each assessed with a different plasma-based NGS method: cohort 1 (n = 127, Guardant360), and cohort 2 (n = 148, FoundationACT/FoundationOne Liquid CDx). Ninety-five patients (75%) in cohort 1 and 108 patients (73%) in cohort 2 underwent concurrent amplicon-based tissue NGS testing locally. Results: Forty-three patients in cohort 1 (34%) and 49 patients in cohort 2 (33%) harbored European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) I or II targetable driver alterations. The addition of orthogonal biopsy (tissue to liquid, or liquid to tissue) offered no relevant clinical value in cases with ESCAT I or II targetable drivers already detected by one method. In contrast, adding orthogonal biopsy incremented the detection of ESCAT I or II targetable drivers not only in cases with uninformative testing (undetectable circulating tumor DNA, unavailable/inadequate tissue) but also in about 5% of the patients with seemingly informative but driver undetected molecular results. The prevalence of ESCAT I or II targetable drivers in plasma was significantly higher in patients with adenocarcinoma, 20 pack-year or less smoking history, and abdominal metastases. Conclusions: Our study suggests that the addition of sequential orthogonal biopsy should be considered whenever an ESCAT I or II targetable driver has not been detected by the initial method, including cases with seemingly informative molecular analysis.

Indexed as

Liquid biopsyNext-generation sequencingNon-small cell lung cancerTargetable driver alterations

Identifiers

PMID39996090
PMCPMC11849081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.